Ian Winchester Flinn MD

PubMed

• Lenalidomide plus rituximab for previously untreated advanced follicular lymphoma: the 10-year RELEVANCE trial analysis.
  Nicolas Gower, Pierre Feugier, Jason R Westin, Jean-Marc Schiano Schiano de Colella, Hervé Tilly
  Blood. 2026-03-31
• 1 citations
  Zanubrutinib for the treatment of patients with del(17p) and/or TP53 CLL/SLL: analysis across clinical studies.
  Constantine S Tam, Mary Ann Anderson, Martin Šimkovič, Paolo Ghia, Ian W Flinn
  Blood Advances. 2026-02-10
• Addition of Ianalumab (VAY736) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia on Ibrutinib Therapy: Results from a Phase Ib Study.
  Kerry A Rogers, Pearlly Yan, Ian W Flinn, Deborah M Stephens, Thomas J Kipps
  Clinical Cancer Research. 2025-12-15

Journal Articles

• CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma  
  Mark P Chao, Sonali M Smith, Ranjana Advani, Ian Flinn, Ravindra Majeti, Nancy L Bartlett, Leslie Popplewell, Justin Kline, Nilanjan Ghosh, Ann LaCasce, The New England Journal of Medicine
• Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma  
  Ian W Flinn, Nancy L Bartlett, The New England Journal of Medicine
• PI3K Inhibitors and the Search for the Holy Grail  
  Ian Flinn, MD, Blood

Abstracts/Posters

• Analysis of an Online Treatment Decision Tool Reveals Variances in Practice between Experts and Oncology Healthcare Providers for Newly Diagnosed Follicular Lymphoma
  Ian W. Flinn, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Final Results of Phase 1, Dose Escalation Study Evaluating ARQ 531 in Patients with Relapsed or Refractory B-Cell Lymphoid Malignancies
  Ian W. Flinn, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Results from a First-in-Human, Proof-of-Concept Phase 1 Trial in Pretreated B-Cell Malignancies for Loxo-305, a Next-Generation, Highly Selective, Non-Covalent BTK Inh...
  Ian W. Flinn, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Lectures

• ZUMA-8: A phase 1/2 multicenter study evaluating KTE-X19 in patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). 
  ASCO Annual Meeting 2019 - Chicago, IL - 6/3/2019
• Effect of dose modifications on response to duvelisib in patients with relapsed/refractory (R/R) CLL/SLL in the DUO trial. 
  ASCO Annual Meeting 2019 - Chicago, IL - 6/3/2019
• Advancing the Role of BTK Inhibitors in B-Cell Malignancies: Expert Guidance for Clinical Management 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019